Metformina + Vildagliptina Generis

Metformin Hydrochloride and Vildagliptin, the active ingredient in Metformina + Vildagliptina Generis, is a biguanide and DPP‑4 inhibitor presented as a strength/form not specified for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Metformina + Vildagliptina Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Vildagliptina Generis combines metformin and vildagliptin to address hyperglycemia in type 2 diabetes.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Adjunct to diet and exercise: enhances overall glycaemic control when lifestyle measures are insufficient. - Combination with insulin therapy: provides additional glucose lowering in patients requiring insulin.

The following adverse reactions have been reported with the combination of metformin and vildagliptin.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia. - Diarrhoea: loose stools occurring especially after treatment initiation. - Headache: mild to moderate intensity. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Severe hypersensitivity reactions: including skin rash, Stevens‑Johnson syndrome, or anaphylaxis.

When prescribing Metformina + Vildagliptina Generis, clinicians should consider several safety aspects.

- Renal function: assess eGFR before initiation and monitor periodically. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia or severe infection. - Pregnancy and lactation: evaluate risk–benefit; limited data are available. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Metformina + Vildagliptina Generis may interact with several medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated due to lactic acidosis risk. - Potent CYP2C9 inhibitors: may increase metformin plasma concentrations. - Co‑administration with other DPP‑4 inhibitors: duplicate therapy should be avoided.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycaemia. - Diuretics (especially thiazides): may affect renal clearance of metformin. - Excessive alcohol intake: heightens lactic acidosis risk.